在用[177Lu]Lu-DOTATATE治疗的神经内分泌瘤中,吸收剂量与反应之间的关系
Carl Fredrik Warfvinge1,2, Johan Gustafsson3, Daniel Roth3
1Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden; carl_fredrik.warfvinge@med.lu.se.
概括
受体放射性核素疗法 (PRRT) 显示出个性化神经内分泌瘤 (NET) 治疗的前景. 这项研究发现,用[177Lu]Lu-DOTATATE治疗的2级NETs中部分瘤反应的剂量值.
科学领域:
- 核医学就是核医学.
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
背景情况:
- 受体放射性核素疗法 (PRRT) 为个性化治疗方案提供剂量测量.
- 用PRRT治疗的神经内分泌瘤 (NETs) 的剂量反应关系尚不清楚.
研究的目的:
- 在用[177Lu]Lu-DOTATATE治疗的NET中研究吸收剂量和瘤反应之间的关系.
- 在NET中确定瘤反应的潜在吸收剂量值.
主要方法:
- 在一项临床试验中,对32名接受[177Lu]Lu-DOTATATE治疗的患者中的69种瘤进行了回顾性分析.
- 用于剂量计量的定量SPECT/CT成像,包括基于voxel的剂量速率计算和部分体积校正.
- 瘤反应通过瘤体积的变化进行评估,并使用混合效应模型和后勤回归进行分析.
主要成果:
- 在2级NET中观察到吸收剂量和体积减少之间的明显关系.
- 至少135 Gy的累积瘤吸收剂量表明,在2级NET中,部分瘤反应的概率为90%.
结论:
- 这些发现与之前关于PRRT中剂量反应关系的研究一致.
- 在2级NET中确定了部分响应的吸收剂量值,告知了用剂量计指导的PRRT.
- 这项研究为优化PRRT治疗方案提供了宝贵的见解.
更多相关视频
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
17.6K
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
9.9K
相关概念视频
Dose-Response Relationship: Overview
3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
